LBRX
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
LB Pharmaceuticals Inc (LBRX) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C- (1.9) | C- (2.0) | C+ (2.8) | F (0.0) | D+ (1.8) |
| 2026-11-06 | F (0.0) | C- (1.9) | C- (2.0) | C+ (2.7) | F (0.0) | D (1.3) |
| 2026-10-30 | F (0.0) | C- (1.9) | C- (2.0) | B- (3.1) | F (0.0) | D (1.4) |
| 2026-10-23 | F (0.0) | C- (1.9) | C- (2.0) | B (3.3) | F (0.0) | D (1.4) |
| 2026-10-16 | F (0.0) | C- (1.9) | C- (2.0) | B+ (3.8) | F (0.0) | D+ (1.5) |